Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:SHPG
- CUSIP: N/A
- Web: www.shire.com
Capitalization:- Market Cap: $49.24377 billion
- Outstanding Shares: 297,854,000
Average Prices:- 52 Week Range: $158.54 - $209.22
P/E:- Trailing P/E Ratio: 168.24
- Foreward P/E Ratio: 10.04
- P/E Growth: 0.83
Sales & Book Value:- Annual Revenue: $13.26 billion
- Price / Sales: 3.68
- Book Value: $98.66 per share
- Price / Book: 1.66
Dividend:- Annual Dividend: $0.91
- Dividend Yield: 0.6%
Profitability:- EBIDTA: $5.31 billion
- Net Margins: 2.14%
- Return on Equity: 13.05%
- Return on Assets: 5.64%
Debt:- Debt-to-Equity Ratio: 0.66%
- Current Ratio: 1.01%
- Quick Ratio: 0.54%
Misc:- Beta: 1.6
- Short Ratio: 0.74
Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)
What is Shire PLC's stock symbol?
Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?
Shire PLC declared a dividend on Friday, February 24th. Shareholders of record on Friday, March 10th will be given a dividend of $0.771 per share on Tuesday, April 25th. The ex-dividend date is Wednesday, March 8th. This is an increase from Shire PLC's previous dividend of $0.14. View Shire PLC's Dividend History.
How were Shire PLC's earnings last quarter?
Shire PLC (NASDAQ:SHPG) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The firm's quarterly revenue was up 109.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.12 earnings per share. View Shire PLC's Earnings History.
What guidance has Shire PLC issued on next quarter's earnings?
Shire PLC issued an update on its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $14.60-15.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.00. The company issued revenue guidance of $14.5-14.8 billion, compared to the consensus revenue estimate of $15.23 billion.
Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?
20 equities research analysts have issued 12-month target prices for Shire PLC's stock. Their predictions range from $198.00 to $325.00. On average, they expect Shire PLC's share price to reach $229.10 in the next twelve months. View Analyst Ratings for Shire PLC.
What are analysts saying about Shire PLC stock?
Here are some recent quotes from research analysts about Shire PLC stock:
- 1. According to Zacks Investment Research, "The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 22% of the total market by the end of Mar 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Earnings estimates have fallen lately ahead of the Q2 results. Shire has a positive record of earnings surprises in the recent quarters." (7/17/2017)
- 2. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)
Who are some of Shire PLC's key competitors?
Some companies that are related to Shire PLC include Eli Lilly and Company (LLY), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG) and Horizon Pharma PLC (HZNP).
Who are Shire PLC's key executives?
Shire PLC's management team includes the folowing people:
- Flemming Ornskov M.D., Chief Executive Officer, Executive Director
- Jeffrey Poulton, Chief Financial Officer, Executive Director
- William Mordan, General Counsel, Company Secretary
- Perry Sternberg, Head - U.S. Commercial
- Kim Stratton, Head - International Commercial
- Philip J. Vickers, Head - Research and Development
- Matthew Walker, Head - Technical Operations
- Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
- Olivier Bohuon, Non-Executive Director
- Ian T. Clark, Non-Executive Director
Who owns Shire PLC stock?
Shire PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.00%), Aperio Group LLC (0.00%), Fisher Asset Management LLC (0.00%), Gateway Investment Advisers LLC (0.00%), US Bancorp DE (0.00%) and Bank of Montreal Can (0.00%). View Institutional Ownership Trends for Shire PLC.
Who sold Shire PLC stock? Who is selling Shire PLC stock?
Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Rockefeller Financial Services Inc., Quantitative Systematic Strategies LLC, Bank of Montreal Can, Catawba Capital Management VA, Leavell Investment Management Inc., Private Trust Co. NA and Fox Run Management L.L.C.. View Insider Buying and Selling for Shire PLC.
Who bought Shire PLC stock? Who is buying Shire PLC stock?
Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, US Bancorp DE, Heritage Investors Management Corp, Altfest L J & Co. Inc., Addison Capital Co, BB&T Corp, Aperio Group LLC and Iberiabank Corp. View Insider Buying and Selling for Shire PLC.
How do I buy Shire PLC stock?
Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire PLC's stock price today?
One share of Shire PLC stock can currently be purchased for approximately $164.03.
MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 15 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $229.10 (39.67% upside) |
Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | BTIG Research | Reiterated Rating | Buy | $242.00 | Low |  |
| 7/13/2017 | Sanford C. Bernstein | Reiterated Rating | Market Perform | $210.00 | Low | |
| 7/12/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $245.00 | Low | |
| 7/11/2017 | Cantor Fitzgerald | Set Price Target | Buy | $222.00 | Medium | |
| 7/6/2017 | HSBC Holdings plc | Upgrade | Reduce -> Hold | | Medium | |
| 6/9/2017 | Jefferies Group LLC | Reiterated Rating | Buy -> Buy | $239.00 -> $216.00 | Low | |
| 6/8/2017 | Royal Bank Of Canada | Set Price Target | Buy | $218.00 | Low | |
| 6/1/2017 | Liberum Capital | Downgrade | Buy -> Hold | | Low | |
| 5/31/2017 | Cowen and Company | Reiterated Rating | Outperform | $325.00 | Low | |
| 4/17/2017 | Goldman Sachs Group, Inc. (The) | Boost Price Target | Overweight | $202.00 -> $214.00 | Low | |
| 3/7/2017 | Barclays PLC | Initiated Coverage | Overweight | | N/A | |
| 2/17/2017 | Guggenheim | Reiterated Rating | Neutral | | N/A | |
| 12/2/2016 | Societe Generale | Initiated Coverage | Buy | | N/A | |
| 11/14/2016 | Leerink Swann | Set Price Target | Buy | $198.00 | N/A | |
| 11/7/2016 | J P Morgan Chase & Co | Reiterated Rating | Overweight | | N/A | |
| 11/3/2016 | Citigroup Inc. | Reiterated Rating | Buy | | N/A | |
| 11/2/2016 | Deutsche Bank AG | Reiterated Rating | Buy | | N/A | |
| 10/23/2016 | BNP Paribas | Reiterated Rating | Buy | | N/A | |
| 10/8/2016 | Shore Capital | Reiterated Rating | Buy | | N/A | |
| 10/1/2016 | Piper Jaffray Companies | Set Price Target | Hold | $201.00 | N/A | |
| 6/3/2016 | Morgan Stanley | Reiterated Rating | Overweight | | N/A | |
| 5/23/2016 | Bryan, Garnier & Co | Initiated Coverage | Buy | | N/A | |
| 3/30/2016 | Bank of America Corporation | Reiterated Rating | Buy | | N/A | |
| 2/13/2016 | Northland Securities | Reiterated Rating | Buy | | N/A | |
| 2/8/2016 | Susquehanna Bancshares Inc | Lower Price Target | Positive | $280.00 -> $220.00 | N/A | |
| 1/18/2016 | Credit Suisse Group | Upgrade | Buy | | N/A | |
| 10/21/2015 | William Blair | Reiterated Rating | Outperform | $276.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for Shire PLC (NASDAQ:SHPG)Earnings History by Quarter for Shire PLC (NASDAQ SHPG)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/2/2017 | Q1 17 | $3.22 | $3.63 | | $3.57 billion | View | Listen | |
| 2/16/2017 | Q416 | $3.24 | $3.37 | $3.78 billion | $3.81 billion | View | N/A | |
| 11/1/2016 | Q316 | $3.21 | $3.17 | $3.57 billion | $3.45 billion | View | N/A | |
| 8/2/2016 | Q216 | $3.03 | $3.38 | $2.28 billion | $2.43 million | View | N/A | |
| 4/29/2016 | Q1 | $3.05 | $3.19 | $1.71 billion | $1.71 billion | View | Listen | |
| 2/11/2016 | Q415 | $2.89 | $2.97 | $1.69 million | $1.72 billion | View | Listen | |
| 10/23/2015 | Q315 | $2.87 | $3.24 | $1.63 billion | $1.58 billion | View | Listen | |
| 7/23/2015 | Q215 | $2.81 | $2.63 | $1.59 billion | $1.56 billion | View | Listen | |
| 4/30/2015 | Q115 | $2.56 | $2.84 | $1.47 billion | $1.49 billion | View | N/A | |
| 2/12/2015 | Q115 | $2.68 | $2.63 | $1.53 billion | $1.58 billion | View | N/A | |
| 10/24/2014 | Q314 | $2.47 | $2.93 | $1.46 billion | $1.55 billion | View | Listen | |
| 7/18/2014 | Q214 | $2.45 | $2.67 | $1.45 billion | $1.50 billion | View | N/A | |
| 5/1/2014 | Q114 | $2.22 | $2.36 | $1.38 billion | $1.35 billion | View | N/A | |
| 2/13/2014 | Q413 | $2.02 | $2.26 | $1.28 billion | $1.33 billion | View | N/A | |
| 10/24/2013 | Q213 | $1.65 | $1.77 | $1.23 billion | $1.24 billion | View | N/A | |
| 7/25/2013 | | $1.60 | $1.79 | $1.21 billion | $1.28 billion | View | N/A | |
| 5/2/2013 | Q113 | $1.56 | $1.63 | $1.21 billion | $1.16 billion | View | N/A | |
| 2/14/2013 | Q412 | $1.58 | $1.58 | $1.20 billion | $1.20 billion | View | N/A | |
| 10/25/2012 | | $1.47 | $1.36 | | | View | N/A | |
| 8/1/2012 | | $1.52 | $1.68 | | | View | N/A | |
| 4/26/2012 | | $0.52 | $1.24 | | | View | N/A | |
| 2/9/2012 | | $0.48 | $0.44 | | | View | N/A | |
| 10/28/2011 | | $1.31 | $1.28 | | | View | N/A | |
| 7/28/2011 | | $1.24 | $1.33 | | | View | N/A | |
| 4/28/2011 | | $1.18 | $1.23 | | | View | N/A | |
| 2/10/2011 | | $1.04 | $1.03 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Shire PLC (NASDAQ:SHPG)2017 EPS Consensus Estimate: $14.75
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | $3.22 | $3.36 | $3.31 |
| Q2 2017 | 4 | $3.53 | $3.69 | $3.60 |
| Q3 2017 | 4 | $3.59 | $3.89 | $3.77 |
| Q4 2017 | 4 | $3.81 | $4.26 | $4.07 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Shire PLC (NASDAQ:SHPG)| Most Recent Dividend: | 4/25/2017 |
| Annual Dividend: | $0.91 |
| Dividend Yield: | 0.55% |
| Payout Ratio: | 122.97% (Trailing 12 Months of Earnings)
6.15% (Based on This Year's Estimates)
5.57% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Shire PLC (NASDAQ SHPG)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/24/2017 | | $0.77 | | 3/8/2017 | 3/10/2017 | 4/25/2017 |
| 8/5/2016 | | $0.14 | | 9/7/2016 | 9/9/2016 | 10/7/2016 |
| 2/11/2016 | | $0.67 | | 3/9/2016 | 3/11/2016 | 4/12/2016 |
| 7/23/2015 | | $0.13 | | 9/2/2015 | 9/4/2015 | 10/2/2015 |
| 2/23/2015 | semiannual | $0.57 | 0.48% | 3/11/2015 | 3/13/2015 | 4/14/2015 |
| 8/4/2014 | semiannual | $0.11 | 0.09% | 9/3/2014 | 9/5/2014 | 10/3/2014 |
| 2/20/2014 | semiannual | $0.51 | 0.61% | 3/5/2014 | 3/7/2014 | 4/8/2014 |
| 7/29/2013 | semiannual | $0.09 | 0.16% | 9/4/2013 | 9/6/2013 | 10/3/2013 |
| 2/19/2013 | semiannual | $0.44 | 0.92% | 3/6/2013 | 3/8/2013 | 4/9/2013 |
(Data available from 1/1/2013 forward)
Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
| Source: |
|
| Date | Headline |
|---|
 | Shire PLC (NASDAQ:SHPG) Expected to Earn FY2017 Earnings of $14.63 Per Share
www.americanbankingnews.com - July 20 at 9:53 AM |
 | Exane Asset Management Buys Monsanto Co, Biogen Inc, Qiagen NV, Sells Citigroup Inc, W R Grace, ...
www.nasdaq.com - July 20 at 7:42 AM |
| FY2018 EPS Estimates for Shire PLC (NASDAQ:SHPG) Decreased by Analyst
www.americanbankingnews.com - July 19 at 1:56 PM |
| William Blair Equities Analysts Lower Earnings Estimates for Shire PLC (SHPG)
www.americanbankingnews.com - July 19 at 9:57 AM |
| Marinus Pharmaceuticals (MRNS) and Shire PLC (NASDAQ:SHPG) Critical Survey
www.americanbankingnews.com - July 18 at 10:19 PM |
| Q2 2017 EPS Estimates for Shire PLC Decreased by SunTrust Banks (NASDAQ:SHPG)
www.americanbankingnews.com - July 18 at 9:35 AM |
| Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific ... - Nasdaq
www.nasdaq.com - July 18 at 8:08 AM |
 | Shire plc (SHPG): Pressure Creates Buying Opportunity - BTIG - StreetInsider.com
www.streetinsider.com - July 18 at 8:08 AM |
 | Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
finance.yahoo.com - July 18 at 8:08 AM |
| Shire plc : Notice of Results
finance.yahoo.com - July 18 at 8:08 AM |
| Shire PLC (NASDAQ:SHPG) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - July 17 at 9:02 PM |
| Shire PLC (NASDAQ:SHPG) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - July 17 at 2:52 PM |
| Shire PLC (NASDAQ:SHPG) Receives Market Perform Rating from Sanford C. Bernstein
www.americanbankingnews.com - July 16 at 7:34 PM |
| Contrasting Shire PLC (NASDAQ:SHPG) and SciClone Pharmaceuticals (SCLN)
www.americanbankingnews.com - July 14 at 10:54 AM |
| 5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
finance.yahoo.com - July 13 at 9:29 AM |
| Shire PLC (NASDAQ:SHPG) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - July 12 at 10:36 AM |
| $3.75 Billion in Sales Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - July 12 at 9:51 AM |
| Stifel Reiterates Buy on Shire plc (SHPG) Following Competitor Data Release - StreetInsider.com
www.streetinsider.com - July 12 at 7:59 AM |
| $3.53 EPS Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - July 10 at 6:18 PM |
| Shire Completes NDA Filing for Hemophilia Drug with FDA - Nasdaq
www.nasdaq.com - July 9 at 12:26 PM |
| Shire PLC (NASDAQ:SHPG) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - July 8 at 2:52 PM |
 | Shire submits iNDA to FDA for SHP654 for treatment of Hemophilia A
seekingalpha.com - July 6 at 9:01 AM |
| Shire Submits Investigational NDA To FDA For Gene Therapy Candidate SHP654
www.nasdaq.com - July 6 at 9:01 AM |
| Shire plc : Additional Listing
finance.yahoo.com - July 6 at 9:01 AM |
| Equities Analysts Set Expectations for Shire PLC's FY2017 Earnings (NASDAQ:SHPG)
www.americanbankingnews.com - July 6 at 8:44 AM |
| Shire PLC (SHPG) Rating Increased to Hold at HSBC Holdings plc
www.americanbankingnews.com - July 6 at 7:46 AM |
 | Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A
feeds.benzinga.com - July 6 at 7:38 AM |
| 3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher
finance.yahoo.com - July 5 at 10:39 AM |
| Shire plc : Total voting rights
finance.yahoo.com - July 4 at 7:20 AM |
| Shire plc : Director/PDMR Shareholding
finance.yahoo.com - July 4 at 7:20 AM |
| Shire PLC (NASDAQ:SHPG) PT Set at $222.00 by Cantor Fitzgerald
www.americanbankingnews.com - July 3 at 6:25 PM |
| Shire PLC (SHPG) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 1 at 3:42 PM |
| Shire PLC (SHPG) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 27 at 2:39 PM |
| Biocryst and Shire under pressure on FDA approval of Behring's HAE med
seekingalpha.com - June 25 at 6:26 AM |
| Shire PLC (SHPG) Upgraded at BidaskClub
www.americanbankingnews.com - June 23 at 5:54 PM |
| SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA
feeds.benzinga.com - June 23 at 8:46 AM |
| EMA accepts Shire's marketing application for recombinant therapy for inherited bleeding disorder; shares ahead 2% premarket
seekingalpha.com - June 22 at 6:36 PM |
| Shire plc (SHPG) Granted Marketing Authorization from EMA for Veyvondi
www.streetinsider.com - June 22 at 6:36 PM |
| Shire wins FDA approval for new ADHD drug
finance.yahoo.com - June 22 at 6:35 PM |
| Shire Announces EMA Validation of Veyvondi Marketing Authorization Application for Treatment of Von Willebrand Disease
finance.yahoo.com - June 22 at 6:35 PM |
| Supernus Pharma (SUPN) Announces Partner, Shire PLC (SHPG), Granted FDA Approval for Mydayis for ADHD - StreetInsider.com
www.streetinsider.com - June 22 at 1:34 PM |
| Shire plc (SHPG) Granted Marketing Authorization from EMA for Veyvondi - StreetInsider.com
www.streetinsider.com - June 22 at 1:34 PM |
| Could Shire PLC (SHPG) Be a Great Stock for Value Investors? - Nasdaq
www.nasdaq.com - June 20 at 7:38 AM |
| Could Shire PLC (SHPG) Be a Great Stock for Value Investors?
finance.yahoo.com - June 20 at 7:37 AM |
| Shire PLC (SHPG) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - June 16 at 8:08 PM |
| Shire PLC (SHPG) Research Coverage Started at Cantor Fitzgerald
www.americanbankingnews.com - June 16 at 10:06 AM |
| $3.54 EPS Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - June 14 at 6:24 PM |
| Shire Investors Have Overreacted To Lialda News - Seeking Alpha
seekingalpha.com - June 14 at 8:07 AM |
| 10 High-Quality Foreign-Stock Bargains
finance.yahoo.com - June 14 at 8:07 AM |
| Shire PLC to Post Q2 2017 Earnings of $3.53 Per Share, Jefferies Group Forecasts (SHPG)
www.americanbankingnews.com - June 12 at 7:10 AM |
Shire PLC (SHPG) Chart for Sunday, July, 23, 2017
